Evaluating Personalized Prescribing Inc. Pharmacogenomic Profiling (Rx Report) for Optimizing Treatment in Patients with Depressive Disorders: An Ambulatory-Care, Delayed-Access Randomized Controlled Trial
We will be conducting a randomized controlled clinical trial to assess the impact of PPI’s pharmacogenomic profiling report (Rx Report) on clinical outcomes in patients with depressive disorders. The trial protocol received the Research Ethics Board (REB) approval to proceed. We invite you to participate in our clinical trial if you are eligible.
Studies indicate that that only half of patients respond to initial treatment with a first-line antidepressant medication. This may be due to common genetic variations in individuals. There have been multiple randomized controlled trials in various settings that indicate that pharmacogenomics testing may assist physicians in medication changes when they fail.
To date, the available trials used tests that included mostly pharmacokinetic genes (e.g., P450 for drug metabolism) and some pharmacodynamic genes (e.g., HTR2A, SLC6A4 for target receptors). The total number of tested genes ranged from 8 to 18, which might not be enough for precise recommendations.
Further, the reporting was via software generated reports without any interpretation of the information by a trained psychopharmacist. These test results are often confusing for physicians and their patients. As a result, most trials showed that pharmacogenomics testing produced moderately better outcomes compared to treatment as usual.
Personalized Prescribing Inc. understand the limitation of above studies; we have developed a comprehensive genetic panel (Rx Report) that includes more than 50 genes relevant to pharmacokinetics and pharmacodynamics of antidepressant medications. We also included specially trained pharmacists for interpreting the genetic results and for producing clear recommendations to physicians for optimizing or switching antidepressant medications.
Our patients have been getting significantly better outcomes using our psychopharmacist’s recommendation based on Rx Report. The outcomes include better treatment response and lower incidents of side-effects.
Help us help others! Please participate in the trial!
Participating patients will receive $100 CAD when they complete the trial.